Cipla Q1 Profit Surges 17.77% to Rs 1,175.46 Crore
By Rediff Money Desk, New Delhi Jul 26, 2024 16:27
Cipla Ltd reported a 17.77% rise in consolidated net profit to Rs 1,175.46 crore in Q1 FY24, driven by strong performance in India and the US. Read more.
New Delhi, Jul 26 (PTI) Pharma major Cipla Ltd on Friday reported a 17.77 per cent rise in consolidated net profit at Rs 1,175.46 crore in the first quarter ended June 30, 2024.
The company had posted a consolidated net profit of Rs 998.07 crore in the first quarter of the last fiscal, Cipla Ltd said in a regulatory filing.
Consolidated total revenue from operations during the quarter under review stood at Rs 6,693.94 crore as against Rs 6,328.89 crore in the year-ago period, it added.
Total expenses in the first quarter were higher at Rs 5,242.77 crore as compared to Rs 5,090.58 crore in the corresponding period last fiscal.
"Our 'One-India' business continued on its growth trajectory during the quarter, led by branded prescription which grew at 10 per cent. Our concentrated focus and execution in the differentiated portfolio have further strengthened the US business which yet again posted all-time high quarterly revenue at USD 250 million," Cipla Ltd MD and Global CEO, Umang Vohra said.
In South Africa, he said, "We recorded a solid growth of 19 per cent Y-o-Y in local currency terms, led by the private market."
Going ahead, Vohra said, "Focus will be on growing our key markets, further building our flagship brands, investing in the future pipeline as well as focusing on resolutions on the regulatory front.
The company had posted a consolidated net profit of Rs 998.07 crore in the first quarter of the last fiscal, Cipla Ltd said in a regulatory filing.
Consolidated total revenue from operations during the quarter under review stood at Rs 6,693.94 crore as against Rs 6,328.89 crore in the year-ago period, it added.
Total expenses in the first quarter were higher at Rs 5,242.77 crore as compared to Rs 5,090.58 crore in the corresponding period last fiscal.
"Our 'One-India' business continued on its growth trajectory during the quarter, led by branded prescription which grew at 10 per cent. Our concentrated focus and execution in the differentiated portfolio have further strengthened the US business which yet again posted all-time high quarterly revenue at USD 250 million," Cipla Ltd MD and Global CEO, Umang Vohra said.
In South Africa, he said, "We recorded a solid growth of 19 per cent Y-o-Y in local currency terms, led by the private market."
Going ahead, Vohra said, "Focus will be on growing our key markets, further building our flagship brands, investing in the future pipeline as well as focusing on resolutions on the regulatory front.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.06 (+ 2.15)
- 34055263
- Srestha Finvest
- 0.70 (+ 4.48)
- 23047766
- GTL Infrastructure
- 2.17 (+ 2.36)
- 15511979
- AvanceTechnologies
- 0.90 (+ 4.65)
- 10289706
- Akshar Spintex
- 0.84 (+ 5.00)
- 9473849
MORE NEWS
NSE IX Sees Foreign Investor Growth on India's...
NSE IX, a multi-asset exchange in India, has witnessed a surge in foreign investor...
Apollo Green Energy IPO: Rs 10,000 Cr Project...
Apollo Green Energy (AGEL) plans to go public in 2025, aiming to build a Rs 10,000...
Anti-Dumping Duty on PVC Resins from 7 Countries
India's DGTR recommends anti-dumping duty on PVC resins from China, US, Korea and...